Trial Profile
Phase 2 Study of HKI-272 in Subjects With Advanced Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Neratinib (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Sponsors Puma Biotechnology
- 26 Jun 2018 Status changed from active, no longer recruiting to completed.
- 09 Dec 2017 Results (n=966) of pooled subgroup analysis of NCT00445458, NCT00706030, NCT00398567, NCT00915018, NCT00741260 and NCT00300781trials assessing safety and efficacy of neratinib therapy in Asian patients from China, Hong Kong, Japan, Korea, Malaysia, Singapore, and Taiwan presented at the 40th Annual San Antonio Breast Cancer Symposium
- 10 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.